18F-DCFPyL PET/CT in the Evaluation of Patients With Biochemical Recurrence of Prostate Cancer and Non-Contributory CT Scans
Phase of Trial: Clinical Phase Unknown
Latest Information Update: 15 Jul 2019
Price : $35 *
At a glance
- Drugs 18F DCFPyL (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Diagnostic use; Expanded access
- 06 May 2019 According to a Progenics Pharmaceuticals media release, data from this trial were presented at the American Urological Association (AUA) Annual Meeting 2019.
- 06 May 2019 Results presented in the Progenics Pharmaceuticals media release.
- 31 Aug 2018 Biomarkers information updated